Total Payments
$1.2M
2024 Payments
$137,030
Companies
29
Transactions
1,054
Medicare Patients
42,826
Medicare Billing
$31.4M
Payment Breakdown by Category
Other$838,060 (70.4%)
Consulting$164,945 (13.9%)
Travel$136,589 (11.5%)
Food & Beverage$31,467 (2.6%)
Research$18,952 (1.6%)
Education$89.10 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $819,772 | 170 | 68.9% |
| Consulting Fee | $164,945 | 47 | 13.9% |
| Travel and Lodging | $136,589 | 294 | 11.5% |
| Food and Beverage | $31,467 | 506 | 2.6% |
| Unspecified | $18,952 | 20 | 1.6% |
| Honoraria | $12,790 | 9 | 1.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $5,244 | 6 | 0.4% |
| Current or prospective ownership or investment interest | $254.69 | 1 | 0.0% |
| Education | $89.10 | 1 | 0.0% |
Payments by Type
General
$1.2M
1,034 transactions
Research
$18,952
17 transactions
Ownership
$0
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $494,419 | 419 | $0 (2024) |
| Genentech USA, Inc. | $211,776 | 196 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $171,259 | 100 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $101,541 | 86 | $0 (2021) |
| Biogen, Inc. | $78,847 | 41 | $0 (2024) |
| Roche Products Limited | $30,769 | 7 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $25,482 | 30 | $0 (2024) |
| F. Hoffmann-La Roche AG | $23,227 | 14 | $0 (2023) |
| Bausch & Lomb Americas Inc. | $17,866 | 35 | $0 (2024) |
| Alimera Sciences, Inc. | $10,320 | 23 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $137,030 | 98 | Regeneron Healthcare Solutions, Inc. ($67,954) |
| 2023 | $259,293 | 172 | Regeneron Healthcare Solutions, Inc. ($92,181) |
| 2022 | $250,875 | 196 | Genentech USA, Inc. ($65,627) |
| 2021 | $82,276 | 81 | Regeneron Healthcare Solutions, Inc. ($60,846) |
| 2020 | $55,434 | 69 | Regeneron Healthcare Solutions, Inc. ($17,702) |
| 2019 | $217,703 | 201 | Regeneron Healthcare Solutions, Inc. ($98,630) |
| 2018 | $110,377 | 131 | Regeneron Healthcare Solutions, Inc. ($63,407) |
| 2017 | $77,114 | 106 | Regeneron Healthcare Solutions, Inc. ($33,216) |
All Payment Transactions
1,054 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,311.00 | General |
| Category: Ophthalmology | ||||||
| 12/19/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $8.50 | General |
| Category: EYE CARE | ||||||
| 12/18/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $32.93 | General |
| Category: Ophthalmology | ||||||
| 12/16/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $25.56 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/03/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $31.78 | General |
| Category: Ophthalmology | ||||||
| 11/22/2024 | Roche Products Limited | Vabysmo (Drug) | Consulting Fee | Cash or cash equivalent | $11,550.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/22/2024 | Roche Products Limited | Vabysmo (Drug) | Travel and Lodging | Cash or cash equivalent | $625.49 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/22/2024 | Roche Products Limited | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $178.35 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/22/2024 | Roche Products Limited | Vabysmo (Drug) | Travel and Lodging | Cash or cash equivalent | $141.60 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/21/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,460.00 | General |
| Category: Ophthalmology | ||||||
| 11/04/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $9.83 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/29/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Travel and Lodging | In-kind items and services | $976.34 | General |
| Category: Ophthalmology | ||||||
| 10/29/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Travel and Lodging | In-kind items and services | $876.96 | General |
| Category: Ophthalmology | ||||||
| 10/29/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $122.13 | General |
| Category: Ophthalmology | ||||||
| 10/17/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $28.86 | General |
| Category: Ophthalmology | ||||||
| 10/16/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Ophthalmology | ||||||
| 10/15/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $22.98 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/10/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $2,820.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/10/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $1,880.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/10/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $28.75 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/10/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $9.73 | General |
| Category: EYE CARE | ||||||
| 10/09/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $122.67 | General |
| Category: EYE CARE | ||||||
| 09/19/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug), YUTIQ | Honoraria | Cash or cash equivalent | $1,390.00 | General |
| Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 09/17/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $184.04 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/17/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $15.69 | General |
| Category: OPHTHALMOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY | Regeneron Pharmaceuticals, Inc. | $8,567 | 5 |
| EYLEA CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $5,411 | 6 |
| A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration | Regeneron Pharmaceuticals, Inc. | $2,480 | 3 |
| Faricimab Personalised Treat-and-Extend-Based Dosing Dynamics in Patients With DME | F. Hoffmann-La Roche AG | $1,310 | 1 |
| Faricimab Personalized Treat-and-Extend-based Dosing Dynamics in Patients With DME | F. Hoffmann-La Roche AG | $841.47 | 1 |
| VA2 PhIII Yosemite | F. Hoffmann-La Roche AG | $342.86 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 39 | 11,915 | 84,491 | $27.1M | $9.5M |
| 2022 | 34 | 10,956 | 50,104 | $20.8M | $7.8M |
| 2021 | 35 | 10,044 | 41,505 | $18.3M | $7.1M |
| 2020 | 35 | 9,911 | 39,862 | $17.3M | $7.0M |
Total Patients
42,826
Total Services
215,962
Medicare Billing
$31.4M
Procedure Codes
143
All Medicare Procedures & Services
143 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 366 | 4,128 | $5.2M | $2.8M | 54.7% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 298 | 6,023 | $4.8M | $1.3M | 27.3% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 172 | 39,420 | $2.5M | $1.1M | 44.4% |
| J3490 | Unclassified drugs | Office | 2023 | 199 | 561 | $1.9M | $887,932 | 47.7% |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | Office | 2023 | 197 | 4,540 | $1.8M | $798,733 | 44.5% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 2,401 | 6,369 | $1.1M | $650,264 | 57.6% |
| 67028 | Injection of drug into eye | Office | 2023 | 1,075 | 4,470 | $4.5M | $508,178 | 11.4% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 112 | 3,390 | $1.4M | $408,023 | 29.9% |
| 92134 | Imaging of retina | Office | 2023 | 2,910 | 8,663 | $1.1M | $289,979 | 26.8% |
| 67039 | Destruction of eye fluid (vitreous) between lens and retina using a laser | Facility | 2023 | 87 | 108 | $492,010 | $86,255 | 17.5% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 35 | 483 | $231,900 | $75,271 | 32.5% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 68 | 70 | $321,025 | $66,237 | 20.6% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 36 | 336 | $169,040 | $58,232 | 34.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 253 | 253 | $55,728 | $32,109 | 57.6% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 228 | 254 | $46,186 | $30,541 | 66.1% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 1,401 | 2,495 | $499,000 | $30,352 | 6.1% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 294 | 393 | $49,215 | $30,215 | 61.4% |
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | Facility | 2023 | 25 | 25 | $119,948 | $25,133 | 21.0% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Facility | 2023 | 66 | 80 | $128,000 | $21,020 | 16.4% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 196 | 196 | $46,362 | $20,887 | 45.1% |
| 67113 | Complex repair of detached retina and drainage of eye fluid between lens and retina | Facility | 2023 | 16 | 18 | $87,370 | $18,930 | 21.7% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 91 | 251 | $28,918 | $18,028 | 62.3% |
| 66820 | Removal of recurring cataract in lens capsule by stab incision | Facility | 2023 | 68 | 79 | $63,200 | $16,596 | 26.3% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 520 | 675 | $135,000 | $12,706 | 9.4% |
| 67040 | Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser | Facility | 2023 | 13 | 15 | $68,917 | $12,462 | 18.1% |
About Dr. Nathan Steinle, M.D
Dr. Nathan Steinle, M.D is a Ophthalmology healthcare provider based in Santa Barbara, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/25/2008. The National Provider Identifier (NPI) number assigned to this provider is 1942455423.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nathan Steinle, M.D has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $137,030 received in 2024. These payments were reported across 1,054 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($819,772).
As a Medicare-enrolled provider, Steinle has provided services to 42,826 Medicare beneficiaries, totaling 215,962 services with total Medicare billing of $31.4M. Data is available for 4 years (2020–2023), covering 143 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Ophthalmology, Ophthalmology
- Location Santa Barbara, CA
- Active Since 11/25/2008
- Last Updated 06/06/2022
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1942455423
Products in Payments
- EYLEA (Biological) $291,043
- Lucentis (Biological) $125,035
- EYLEA HD (Biological) $119,499
- Syfovre (Drug) $111,046
- EYLEA AFLIBERCEPT INJECTION (Biological) $109,359
- VABYSMO (Drug) $83,604
- BEOVU (Drug) $48,327
- Vabysmo (Drug) $42,650
- XIPERE (Drug) $18,142
- ILUVIEN (Drug) $6,314
- Non-Covered Product (Drug) $3,328
- Iluvien (Biological) $2,769
- TYRVAYA (Drug) $1,922
- OZURDEX (Drug) $1,634
- VUITY (Drug) $1,550
- Constellation (Device) $668.41
- DOCTORS ALLERGY FORMULA (Device) $349.81
- SUSVIMO (Drug) $264.19
- DEXTENZA (Drug) $261.59
- VYZULTA (Drug) $206.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Santa Barbara
Dr. Douglas Katsev, Md, MD
Ophthalmology — Payments: $825,853
Ophthalmology $825,853
Daniel Learned, M.d, M.D
Ophthalmology — Payments: $43,350
Ophthalmology $43,350
Michael Paveloff, Md, MD
Ophthalmology — Payments: $40,714
Ophthalmology $40,714
Dr. Stephen Couvillion, Md, MD
Ophthalmology — Payments: $27,316
Ophthalmology $27,316
Dr. Stuart Winthrop, M.d, M.D
Ophthalmology — Payments: $5,752
Ophthalmology $5,752
Dr. Robert Poulin, M.d, M.D
Ophthalmology — Payments: $4,450
Ophthalmology $4,450